The CCB Program Area has 24 core members, distributed among these three focus areas. During the current funding year, peer-reviewed funding totaled $12 million in total costs, including $1.45 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CCB Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CCB Program Area total $1,042,520. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. Cancer Cell Biology Program Area members published 201 peer-reviewed papers during the recent five-year renewal period. The JCCC CCB program area is highly interactive, with 9% of its 201 publications reflecting intraprogrammatic efforts and 59% reporting inter-programmatic collaborations. 129 publications (64%) appeared in high-impact journals. The Cancer Cell Biology (CCB) Program Area was previously named the """"""""Molecular, Cellular and Developmental Biology (MCDB) Program Area."""""""" In response to the 2002 CCSG review, and in extensive consultation with our External Advisory Board, the JCCC has reorganized this program. The goals of the reorganization were to: (1) identify critical cancer-relevant focus areas of basic science and biomedical technologies;(2) identify appropriate leaders and members for these focus areas;(3) promote intraprogrammatic interactions and collaborations within and across these groups in cancer-related areas;and (4) foster inter-programmatic interactions leading to translational and clinical collaboration. Concomitantly with the interest in reorganizing this program area, UCLA had made the strategic decision to invest heavily in infrastructure, faculty recruitment and funding in nanotechnology and stem cell biology;the California NanoSystems Institute and the Broad Stem Cell Center (BSCC) have both been created during the current JCCC CCSG funding cycle, and new buildings constructed to house these programs. The JCCC capitalized and incorporated the investment made by UCLA into our Program Area strategic plan and identified three main interest groups for the Cancer Cell Biology Program Area: (1) nanobiology applications to cancer detection, monitoring, and therapy;(2) cancer stem cell identification and eradication;and (3) model organism studies of cancer detection, progression, and therapy. Senior Associate Dean Dr. Leonard Rome, the former MCDB Program Area director, has become the JCCC Director for Strategic Planning and Partnerships. With the enthusiastic support of our EAB, Dr. Luisa Iruela-Arispe, an internationally known developmental biologist and cancer researcher has become the Director of the CCB Program Area. Dr. Michael Teitell, a pathologist and cancer biologist with strong interests in nanotechnology, brings strength in this area and a clinical perspective to the Co-Director position.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Patananan, Alexander N; Sercel, Alexander J; Teitell, Michael A (2018) More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol 3:16-24
Heard, Jeffrey J; Phung, Ivy; Potes, Mark I et al. (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18:69
Kim, Roy Y; Mangu, Darian; Hoffman, Alexandria S et al. (2018) Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis. Brain 141:132-147
Pothoulakis, Charalabos; Torre-Rojas, Monica; Duran-Padilla, Marco A et al. (2018) CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis. Int J Cancer 142:334-346
Montecino-Rodriguez, Encarnacion; Casero, David; Fice, Michael et al. (2018) Differential Expression of PU.1 and Key T Lineage Transcription Factors Distinguishes Fetal and Adult T Cell Development. J Immunol 200:2046-2056
Black, David S; Cole, Steve W; Christodoulou, Georgia et al. (2018) Genomic mechanisms of fatigue in survivors of colorectal cancer. Cancer 124:2637-2644
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Chua, Bernadette Anne; Ngo, Jamie Ann; Situ, Kathy et al. (2018) Protein S and Gas6 induce efferocytosis of HIV-1-infected cells. Virology 515:176-190
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830

Showing the most recent 10 out of 767 publications